February, 2003
© 2000 Scott S. Emerson, M.D., Ph.D.
Session
4:
57
Case Study 1: Idarubicin in AML
Idarubicin in Acute Myelogenous Leukemia
Patients randomized to receive Idarubicin (Ida) or
Daunorubicin (Dnr) in equal numbers
Primary response: Induction of complete remission
Secondary response: Survival